Stealth BioTherapeutics to Present at 2022 H.C. Wainwright BioConnect Virtual Conference
Stealth BioTherapeutics Corp (Nasdaq: MITO) announced that CEO Reenie McCarthy will present at the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. The presentation will be available for on-demand viewing starting January 10 at 7:00 a.m. ET on the company's website. Stealth focuses on therapies for mitochondrial dysfunction, with lead candidate elamipretide targeting conditions like Barth syndrome and age-related diseases. The company is also developing second-generation candidate SBT-272 and new compounds SBT-550 for neurological diseases.
- None.
- None.
BOSTON, Jan. 4, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the H.C. Wainwright BioConnect Virtual Conference taking place from January 10-13, 2022. The presentation will be available for on-demand viewing starting Monday, January 10, 2022 at 7:00 a.m. ET.
An on-demand webcast of the presentation will be available on the Investors & News section of Stealth's website at https://investor.stealthbt.com/. A replay of the webcast will be archived on Stealth's website for 30 days following the event.
About Stealth
We are a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases and are involved in many common age-related diseases, typically involving organ systems with high energy demands such as the heart, the eye, and the brain. We believe our lead product candidate, elamipretide, has the potential to treat both rare metabolic cardiomyopathies, such as Barth syndrome, DMD and Friedreich's ataxia, primary mitochondrial myopathy caused by nuclear DNA mutations, as well as ophthalmic diseases entailing mitochondrial dysfunction, such as dry age-related macular degeneration and Leber's hereditary optic neuropathy. We are evaluating our second-generation clinical-stage candidate, SBT-272, and our new series of small molecules, SBT-550, for rare neurological disease indications following promising preclinical data. We have optimized our discovery platform to identify novel mitochondria-targeted compounds which may be nominated as therapeutic product candidates or utilized as mitochondria-targeted vectors to deliver other compounds to mitochondria.
Investor Relations
Stern Investor Relations
Janhavi Mohite, 212-362-1200
IR@StealthBT.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/stealth-biotherapeutics-to-present-at-2022-hc-wainwright-bioconnect-virtual-conference-301453070.html
SOURCE Stealth BioTherapeutics Inc.
FAQ
When will Stealth BioTherapeutics present at the H.C. Wainwright BioConnect Virtual Conference?
What time will Stealth BioTherapeutics' presentation be available for viewing?
Where can I find the webcast of Stealth BioTherapeutics' presentation?
What is the focus of Stealth BioTherapeutics' research?
What are the main product candidates of Stealth BioTherapeutics?
